GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Glaxo's (GSK) long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral pills.

Glaxo's Long-Acting HIV Injection Effective Than Daily Pills

A company mostly held by GlaxoSmithKline said it's ending its study early after finding long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP in preventing HIV transmission.

Glaxo-held firm ends HIV study early as injectable shows higher efficacy than daily pill

Glaxosmithkline sees its Relative Strength Rating hit the 80-plus level.
The post GlaxoSmithKline's Relative Strength Rating Flashes Healthy Signs appeared first on Investor's Business Daily.

GlaxoSmithKline's Relative Strength Rating Flashes Healthy Signs

CytoDyn Inc.

Gilead Sciences

Regeneron Pharmaceuticals

Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.

Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners

Kraft Heinz

Microsoft

These payouts are in good shape and there's plenty of reason to be bullish on these stocks.

3 Dividend Stocks to Buy That Are Doing Well During the COVID-19 Pandemic

BioNTech SE

Emergent BioSolutions

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

Novavax

Pfizer

Sanofi

Sinovac Biotech

Is There A Safer Way to Invest in a Coronavirus Vaccine?

Bristol-Myers

Eli Lilly

Friday's big stock charts feature pharmaceutical-market names that recently posted terrific earnings data.
The post 3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline appeared first on InvestorPlace.

3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline

Unilever

GlaxoSmithKline  has sold its stake in Unilever's  Indian business  for $3.4 billion, marking India's largest block trade, which will help the British company in its goal of reinvigorating its drug development pipeline.

GSK sells $3.4 billion Hindustan Unilever stake in largest India block trade

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D'Silva)

Britain's GSK to sell entire stake in Hindustan Unilever

Catalent

Vir Biotechnology

Around 70 companies are working on coronavirus treatments. Here are a few with the most promise.

Finding a Coronavirus Cure: 5 Companies Making Moves

Glaxo (GSK) beats on earnings and sales in the first quarter. Strong demand for respiratory drugs and Shingrix along with stockpiling of certain drugs amid COVID-19 drive sales.

Glaxo (GSK) Q1 Earnings Beat on COVID-19-Related Stockpiling

The combined effort of these two companies marks one of the largest manufacturing collaborations on the planet toward a coronavirus vaccine.

Here's Why Investors Should Follow Sanofi and GlaxoSmithKline's New Coronavirus Collaboration

GlaxoSmithKline plc (GSK) CEO Emma Walmsley on Q1 2020 Results - Earnings Call Transcript

Glaxo beats both earnings and sales estimates in the first quarter of 2020. Stock up.

Glaxo (GSK) Beats Earnings & Revenue Estimates in Q1

AbbVie

Johnson & Johnson, AbbVie, and GlaxoSmithKline are all good choices.

3 Healthcare Stocks With Solid Dividends to Hold Through Bumpy Times

Is the high-flying small biotech stock the better choice over the more sluggish big pharma stock?

Better Buy: Inovio Pharmaceuticals vs. GlaxoSmithKline

GlaxoSmithKline (GSK) closed the most recent trading day at $41.05, moving -1.61% from the previous trading session.

GlaxoSmithKline (GSK) Stock Moves -1.61%: What You Should Know

Two big drugmakers. One clear winner for investors.

Better Buy: GlaxoSmithKline vs. Bristol Myers Squibb

You'd be hard-pressed to find better dividend stocks in the market right now.

4 Dirt-Cheap Dividend Stocks to Buy as the Coronavirus Pandemic Continues

Sanofi (SNY) and Glaxo are contributing their proven technologies to develop a coronavirus vaccine, which may be manufactured at large scale.

Sanofi and Glaxo Collaborate to Develop Coronavirus Vaccine

If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.

Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up

If the pharmaceutical giants are successful, their SARS-CoV-2 vaccine could be ready for use next year.

Sanofi and GlaxoSmithKline Join Forces to Develop a Coronavirus Vaccine

"If we're successful … we're hoping to get to hundreds of millions of doses by the end of next year," GlaxoSmithKline CEO Emma Walmsley told CNBC's Jim Cramer.

GlaxoSmithKline CEO calls Covid-19 vaccine partnership with Sanofi an 'unprecedented collaboration'

Pharmaceutical giants Sanofi and GlaxoSmithKline teamed up Tuesday to develop a coronavirus vaccine that could begin testing in late 2020 and potentially launch in the second half of 2021.
The post Covid Report: Sanofi, GSK Unveil Powerhouse Deal For Coronavirus Vaccine appeared first on Investor's Business Daily.

Covid Report: Sanofi, GSK Unveil Powerhouse Deal For Coronavirus Vaccine

COVID-19 vaccine development has become a crowded field, with about 70 players working for a breakthrough, according to the latest estimates by the World Health Organization.

GlaxoSmithKline, Sanofi Collaborate On COVID-19 Vaccine Development: What You Should Know

News for GlaxoSmithKline Stock (GSK)